References
- Rendic S., Di Carlo F. J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. 1997; 29: 413–580
- Clarke S. E. “In vitro assessment of human cytochrome P450. Xenobiotica 1998; 28: 1167–1202
- Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Path. 1996; 24: 45–57
- Smith D. A., Jones B. C. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 1992; 44: 2089–2098
- Lewis D. F.V. Cytochromes P450: Structure, Function and Mechanism. Taylor & Francis, London 1996
- Lewis D. F.V. Quantitative structure-activity relationships in substrates, inducers and inhibitors of cytochrome P4501. Drug Metab. Rev 1997; 29: 589–650
- Lewis D. F.V., Dickins M., Lake B. G., Eddershaw P. J., Tarbit M. H., Goldfarb P. S. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology 1999; 133: 1–33
- Lewis D. F.V., Lake B. G. Molecular modelling of mammalian CYP2B isoforms and their interactions with substrates, inhibitors and redox partners. Xenobiotica 1997; 27: 443–478
- Lewis D. F.V., Eddershaw P. J., Dickins M., Tarbit M. H., Goldfarb P. S. Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chem. Biol. Interact. 1998; 115: 175–199
- Lewis D. F.V., Dickins M., Weaver R. J., Eddershaw P. J., Goldfarb P. S., Tarbit M. H. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed experiments in the CYP2C subfamily. Xenobiotica 1998; 28: 235–268
- Lewis D. F.V., Eddershaw P. J., Goldfarb P. S., Tarbit M. H. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997; 27: 319–340
- Lewis D. F.V., Lake B. G., Bird M. G., Dickins M., Eddershaw P. J., Tarbit M. H., Goldfarb P. S. Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the CYP2E1 isoform. Xenobiotica 2000; 30: 1–25
- Lewis D. F.V., Wiseman A., Tarbit M. H. Molecular modelling of lanosterol 14α-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within a number of antifungal agents. Enz-Inhib. 1999; 14: 175–192
- Lewis D. F.V., Lake B. G., Ioannides C., Parke D. V. Inhibition of hepatic aryl hydrocarbon hydroxylase activity by a series of 7-hydroxycoumarins: QSAR studies. Xenobiotica 1994; 24: 829–838
- Pelkonen O., Rautio A., Raunio H., Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000; 144: 139–147
- Lewis D. F.V., Modi S., Dickins M. Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. 2001, Submitted for publication
- Lewis D. F.V. Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P450 mediated aniline hydroxylation. Chem. Biol. Internet. 1987; 62: 271–280
- Koop D. R. Inhibition of ethanol-inducible cytochrome P450IIE1 by 3-amino-1,2,4-triazole. Chem. Res. Toxicol. 1990; 3: 377–383
- Hargreaves M. B., Jones B. C., Smith D. A., Gescher A. Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metab. Dispn. 1994; 22: 806–810
- Lewis D. F.V. Guide to Cytochromes. Taylor & Francis, London 2001; P450